Do IPAs cause gynaecomastia? It's a question that has gained traction in health forums, fuelled by the known presence of phytoestrogens in hops. India Pale Ales contain higher concentrations of hops than most beers, and hops harbour compounds — particularly 8-prenylnaringenin — that can bind to oestrogen receptors. Whilst the biological mechanism is plausible, the clinical evidence linking IPA consumption directly to gynaecomastia in men drinking at typical levels remains limited. This article examines the science, relevant risk factors, and NHS-aligned guidance on when to seek medical advice.

What Is Gynaecomastia and How Does It Develop?

Gynaecomastia is benign glandular breast tissue enlargement in males caused by an imbalance between oestrogen and androgen activity; it can be triggered by medications, alcohol, recreational drugs, and underlying health conditions.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males. It is a relatively common condition that can affect men and boys at various stages of life, including during puberty, middle age, and older adulthood. It is important to distinguish true gynaecomastia — which involves actual glandular tissue growth — from pseudogynaecomastia, which is caused by excess fatty tissue without glandular proliferation.

The underlying mechanism involves an imbalance between oestrogen and androgen (testosterone) activity in breast tissue. Oestrogens stimulate breast tissue growth, whilst androgens suppress it. When this balance is disrupted — whether through increased oestrogen levels, reduced testosterone, or heightened sensitivity of breast tissue to oestrogen — gynaecomastia can develop. Pubertal gynaecomastia is common and typically resolves spontaneously within 6–24 months without treatment.

Beyond physiological changes, a wide range of factors can contribute to gynaecomastia, including:

• Medications such as spironolactone, finasteride, dutasteride, bicalutamide, digoxin, certain antipsychotics, antidepressants, antiretrovirals, and methadone

• Anabolic steroids and performance-enhancing drugs

• Recreational substances including cannabis and alcohol

• Underlying health conditions such as hypogonadism, liver disease, chronic kidney disease, hyperthyroidism, hyperprolactinaemia, testicular or hCG-secreting tumours, and Klinefelter syndrome

• Herbal or dietary supplements with oestrogenic or anti-androgenic properties

If you are taking a prescribed medicine that you think may be contributing to breast changes, do not stop taking it without first speaking to your GP or prescriber, as this could be harmful.

Understanding the hormonal basis of gynaecomastia is essential when evaluating whether any substance — including India Pale Ales (IPAs) and other hop-heavy beers — could plausibly contribute to its development. The condition is rarely dangerous but can cause significant psychological distress and physical discomfort, making accurate information particularly important for those affected. Further information is available from the NHS and NICE Clinical Knowledge Summary (CKS) on gynaecomastia.

How IPAs May Influence Hormone Levels in Men

IPAs contain the phytoestrogen 8-prenylnaringenin, which can bind oestrogen receptors, but concentrations in beer are low and alcohol's direct suppression of testosterone and impairment of hepatic oestrogen clearance is likely more hormonally significant.

India Pale Ales (IPAs) are a style of beer characterised by a high concentration of hops, which are the dried flowers of the plant Humulus lupulus. Hops are used in brewing primarily to impart bitterness and aroma, but they also contain biologically active compounds that have attracted scientific interest.

Of particular relevance is 8-prenylnaringenin (8-PN), a phytoestrogen found in hops and considered one of the most potent plant-derived oestrogens identified to date. Phytoestrogens are naturally occurring plant compounds that can bind to oestrogen receptors in the human body and exert weak oestrogenic effects. Other relevant compounds in hops include isoxanthohumol and xanthohumol, which can be partially converted to 8-PN through gut metabolism (Possemiers et al., 2005; Bolca et al., 2007). Studies measuring 8-PN in commercially available beers, including IPAs, have found detectable but generally low concentrations — typically in the range of 1–10 µg per litre — suggesting that estimated daily intake from moderate beer consumption is well below levels associated with clinically meaningful oestrogenic effects in most men (Milligan et al., 1999; Stevens et al., 2013).

The theoretical concern is that regular consumption of hop-rich beers such as IPAs could introduce sufficient quantities of these phytoestrogens into the body to subtly shift the oestrogen-to-androgen balance in men. However, it is important to note that:

• The concentration of 8-PN in beer is generally low

• Individual gut microbiome differences affect how much isoxanthohumol is converted to 8-PN, leading to considerable variability in exposure between individuals

• Any phytoestrogen effect from beer at typical drinking levels is likely minimal compared with the hormonal effects of heavy alcohol use

Alcohol's direct impact on the liver — which plays a central role in metabolising hormones — is likely to be equally or more significant than the phytoestrogen content of IPAs. Alcohol suppresses testosterone production; with chronic or heavy use, it also impairs hepatic clearance of oestrogens and increases aromatase activity, raising circulating oestrogen levels regardless of beer type. This distinction between short-term and chronic alcohol effects is clinically important: occasional moderate drinking carries a different risk profile from sustained heavy consumption.

Evidence Linking IPA Consumption to Gynaecomastia

No robust clinical evidence confirms that IPAs directly cause gynaecomastia; available data are indirect, and estimated 8-PN intake from moderate beer consumption falls well below levels associated with clinically meaningful oestrogenic effects.

The question of whether IPAs specifically cause gynaecomastia has circulated in popular health discussions, but the clinical evidence base remains limited and largely indirect. There is currently no official regulatory guidance from the MHRA, NICE, or NHS that identifies IPA consumption or hop phytoestrogens as a recognised cause of gynaecomastia. The available evidence is primarily derived from laboratory studies, animal models, and observational data rather than robust clinical trials.

Laboratory research has confirmed that 8-prenylnaringenin binds to oestrogen receptors with notable affinity (Stevens & Page, 2004; Chadwick et al., 2006). Some early studies in hop-processing workers — predominantly women — reported menstrual irregularities attributed to occupational exposure to high levels of hop phytoestrogens. However, these findings involved direct, prolonged contact with raw hops at concentrations far exceeding those found in a pint of beer, and are therefore of limited relevance to consumer exposure.

In terms of beer consumption specifically, estimated 8-PN intake from moderate drinking is thought to be well below the threshold required to produce clinically meaningful oestrogenic effects in most men, and is considerably lower than phytoestrogen exposure from common dietary sources such as soya-based foods (Walker et al., 2018). That said, individual variability in gut microbiome composition means some people may convert more isoxanthohumol to 8-PN than others, potentially increasing exposure.

It is also worth noting that alcohol consumption broadly — regardless of beer style — is an established contributing factor to gynaecomastia through its effects on liver function, aromatase activity, and testosterone suppression. Heavy or chronic drinking is more likely to be clinically significant than the specific phytoestrogen content of IPAs. Obesity is an additional important confounder, as adipose tissue independently increases aromatase-mediated conversion of androgens to oestrogens.

In summary, whilst a theoretical biological mechanism exists, there is insufficient clinical evidence to confirm that IPAs directly cause gynaecomastia in men drinking at typical levels.

Risk Factors That May Increase Your Likelihood

Key risk factors include obesity, liver disease, hypogonadism, certain medications (e.g. spironolactone, finasteride), anabolic steroid use, and chronic heavy alcohol intake, all of which disrupt the oestrogen-to-androgen balance.

Whilst the evidence linking IPAs specifically to gynaecomastia remains inconclusive, certain individuals may be more susceptible to hormonally mediated breast tissue changes. Understanding these risk factors can help contextualise any potential contribution from dietary or lifestyle sources of phytoestrogens.

Key risk factors for gynaecomastia include:

• Age: Adolescent boys and men over 50 are at higher physiological risk due to natural hormonal fluctuations

• Obesity: Adipose (fat) tissue converts androgens to oestrogens via the enzyme aromatase, raising oestrogen levels

• Liver disease: Impaired hepatic metabolism leads to reduced clearance of oestrogens from the bloodstream

• Chronic kidney disease: Can alter sex hormone metabolism and binding

• Hypogonadism or Klinefelter syndrome: Low testosterone production reduces the counterbalancing effect of androgens on breast tissue

• Hyperprolactinaemia or hyperthyroidism: Endocrine disorders that can disrupt the oestrogen-to-androgen balance

• Testicular or hCG-secreting tumours: Can directly increase oestrogen production or stimulate it indirectly

• Medications: Certain drugs including spironolactone, finasteride, dutasteride, bicalutamide, digoxin, some antipsychotics, antidepressants, antiretrovirals, and methadone are known to increase gynaecomastia risk (see BNF monographs for individual medicines)

• Anabolic steroid use: Exogenous androgens can be aromatised to oestrogens, paradoxically promoting breast tissue growth

• Heavy alcohol use: Chronic alcohol intake suppresses testosterone and impairs oestrogen metabolism

If you are taking a prescribed medicine that appears on this list, do not stop it without first discussing this with your GP or prescriber.

For men who already have one or more of these risk factors, regular consumption of hop-rich beers such as IPAs may theoretically add a modest additional oestrogenic stimulus, though this has not been conclusively demonstrated in clinical studies. Men with pre-existing liver or renal conditions, or those taking medications that affect hormone metabolism, should be particularly mindful, as their baseline hormonal balance may already be compromised.

Lifestyle factors such as maintaining a healthy weight, limiting alcohol intake, and avoiding unnecessary use of supplements with oestrogenic or anti-androgenic properties (such as certain herbal products) are sensible general measures for reducing overall gynaecomastia risk. If you suspect a herbal supplement or medicine is causing a side effect, you can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

When to Seek Medical Advice from Your GP

See your GP promptly if you notice a new breast lump, rapid enlargement, nipple discharge or skin changes, or asymmetrical swelling; NICE NG12 recommends urgent 2-week-wait referral for men aged 30 and over with an unexplained breast lump.

Most cases of gynaecomastia are benign and self-limiting, particularly when they occur during puberty. However, there are circumstances in which it is important to seek prompt medical assessment from your GP to rule out underlying conditions or, in rare cases, more serious pathology.

You should contact your GP if you notice:

• A new lump or swelling in one or both breasts

• Breast tissue that is tender, painful, or rapidly enlarging

• Nipple discharge, retraction, or skin changes of any kind

• Asymmetrical breast enlargement, particularly affecting only one side

• Swollen lymph nodes in the armpit

• Breast changes accompanied by other symptoms such as fatigue, unexplained weight loss, or testicular changes

• Persistent gynaecomastia lasting more than two years, particularly in adolescents

Urgent referral: In line with NICE guideline NG12 (Suspected Cancer: Recognition and Referral), GPs should consider an urgent 2-week-wait referral to a breast clinic for men aged 30 and over with an unexplained breast lump, and for men aged 50 and over with unilateral nipple changes such as discharge or retraction. Men with other suspicious features should also be considered for urgent referral. Whilst male breast cancer is rare — accounting for less than 1% of all breast cancer cases in the UK — unexplained breast changes should not be dismissed without professional evaluation.

Your GP will take a thorough history, including details of any medications, recreational substances, alcohol intake, and dietary supplements. Initial investigations typically include blood tests to assess hormone levels (testosterone, oestradiol, LH, FSH, prolactin, hCG, and SHBG), thyroid function (TSH), liver function tests (LFTs), and renal profile. A testicular examination will usually be performed, and testicular ultrasound arranged if a tumour is suspected. If a discrete breast lump is identified, referral to a one-stop breast clinic for triple assessment (clinical examination, imaging, and biopsy if indicated) is the standard pathway.

If you are concerned that your IPA consumption or alcohol intake may be contributing to breast changes, it is entirely appropriate to raise this with your GP. Reducing alcohol intake is a reasonable and evidence-supported step whilst awaiting assessment. The UK Chief Medical Officers' low-risk drinking guidelines recommend that both men and women consume no more than 14 units of alcohol per week, spread across three or more days, with several alcohol-free days each week.

NHS Guidance on Managing Gynaecomastia

NHS management ranges from watchful waiting and addressing reversible causes to off-label pharmacological treatment (e.g. tamoxifen) initiated by a specialist, or surgical intervention for persistent, distressing cases subject to local ICB criteria.

The NHS recognises gynaecomastia as a common and usually benign condition. Management is guided by the underlying cause, the severity of symptoms, and the degree of distress experienced by the individual. In many cases, particularly in adolescent boys, no active treatment is required as the condition resolves spontaneously within 6–24 months.

NHS-aligned management approaches include:

• Watchful waiting: For mild or physiological gynaecomastia, monitoring over time is often the first-line approach

• Addressing reversible causes: Stopping or switching medications known to cause gynaecomastia (only under medical supervision), reducing alcohol intake, or treating an underlying condition (such as hypogonadism or hyperthyroidism) can lead to resolution

• Pharmacological treatment: In some cases, short-term use of medicines such as tamoxifen (a selective oestrogen receptor modulator) or aromatase inhibitors may be considered. These are used off-label in the UK for gynaecomastia — they are not licensed specifically for this indication — and should only be initiated by a specialist (typically an endocrinologist or breast surgeon) for recent-onset or painful gynaecomastia after reversible causes have been addressed. The evidence base is limited, and a careful risk–benefit discussion and appropriate monitoring for adverse effects are required. Refer to the BNF and individual Summary of Product Characteristics (SmPC) for prescribing information. The European Academy of Andrology (EAA) clinical practice guideline on gynaecomastia provides a useful evidence-based management algorithm

• Surgical intervention: For persistent, symptomatic, or psychologically distressing gynaecomastia, surgical options including liposuction or mastectomy may be considered via NHS referral. Access is subject to local NHS Integrated Care Board (ICB) policies and, in some areas, Individual Funding Request (IFR) criteria

NICE does not currently have a dedicated guideline specifically for gynaecomastia, but management is informed by broader endocrinology and breast surgery guidance, including NICE CKS. Referral to an endocrinologist or breast surgeon may be appropriate depending on the clinical findings.

From a lifestyle perspective, the NHS advises men to maintain a healthy weight, limit alcohol consumption to within the UK CMO recommended guidelines (no more than 14 units per week for men and women, spread over three or more days), and discuss any concerns about medications or supplements with a healthcare professional. Whilst there is no official NHS guidance specifically addressing IPA consumption and gynaecomastia, reducing overall alcohol intake remains a sensible and evidence-supported measure for men experiencing unexplained breast changes.

If you suspect that a medicine or herbal supplement is causing a side effect such as gynaecomastia, you can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

Frequently Asked Questions